David H Fitchett

基本信息

Career Trajectory

Bio

Dr Fitchett has more than 190 reviewed publications, abstracts, and book chapters. His research interests are clinical trials in acute coronary syndromes and the impact of diabetes and metabolic syndrome on heart disease.

Research Interests

Papers共 90 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Effect of Qualifying Atherosclerotic Cardiovascular Disease Diagnosis Proximity on Cardiovascular Risk and Benefit of Empagliflozin in the EMPA-REG OUTCOME Trial

Ayodele Odutayo,Bernard Zinman,Christoph Wanner,Isabella Zwiener,Soren S. Lund,Stefan Hantel,David Fitchett,Jacob A. Udell

CJC open (2024)

Cited0Views0WOSBibtex

Empagliflozin Reduces the Total Burden of All-cause Hospitalisations and All-cause Mortality in the EMPA-REG OUTCOME Trial

Silvio E. Inzucchi,Bernard Zinman,Christoph Wanner,David Fitchett,Stefan D. Anker,Stuart Pocock,Stefan Kaspers,Jyothis T. George,Odd Erik Johansen,Waheed Jamal,Stefan Hantel,Soren S. Lund

Diabetologie und Stoffwechsel（2021）

Cited0Views0Bibtex

Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes

Abhinav Sharma,Anne Pernille Ofstad,Tariq Ahmad,Bernard Zinman,Isabella Zwiener,David Fitchett,Christoph Wanner,Jyothis T. George,Stefan Hantel,Nihar Desai,Robert J. Mentz

JACC: Heart Failureno. 8 (2021): 568-577

Cited4Views0Bibtex

Relationship Between Hypoglycaemia, Cardiovascular Outcomes, and Empagliflozin Treatment in the EMPA-REG OUTCOME® Trial

David Fitchett,Silvio E. Inzucchi,Christoph Wanner,Michaela Mattheus,Jyothis T. George,Ola Vedin,Bernard Zinman,Odd Erik Johansen

EUROPEAN HEART JOURNAL（2020）

Cited30Views0WOSBibtex

The Canadian Consensus Working Group’s Approach to Identifying and Managing Statin-Associated Muscle and Other Symptoms

G. B. John Mancini,Jean Bergeron,David Fitchett,Jacques Genest,Milan Gupta,Robert A. Hegele,Dominic Ng,Glen J. Pearson,Janet Pope

Contemporary CardiologyStatin-Associated Muscle Symptomspp.137-150, (2020)

Cited0Views0Bibtex

131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome

Silvio E. Inzucchi,Bernard Zinman,Christoph Wanner,David H. Fitchett, Stefan Anker,Stuart Pocock,Stefan Kaspers,Jyothis T. George,Odd Erik Johansen,Waheed Jamal,Stefan Hantel,Soren S. Lund

Diabetes（2020）

Cited1Views0Bibtex

EMPAGLIFLOZIN IS ASSOCIATED WITH A LOWER RISK OF POST-ACUTE HEART FAILURE REHOSPITALIZATION AND MORTALITY: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL

Gianluigi Savarese,Naveed Sattar,James Januzzi,Subodh Verma,Lars H. Lund,David Fitchett,Cordula Zeller,Jyothis T. George,Martina Brueckmann,Anne Pernille Ofstad,Silvio E. Inzucchi,Christoph Wanner,Bernard Zinman,Javed Butler

CIRCULATION（2019）

Cited48Views0WOSBibtex

To Risk Stratify or Not for Statin Therapy

David Fitchett

Canadian journal of cardiology（2019）

Cited0Views0Bibtex

Abstract 11455: Empagliflozin in Resistant Hypertension: Findings from the Empa-reg Outcome Trial

João Pedro Ferreira,David Fitchett,Anne Pernille Ofstad,Bettina Kraus,Christoph Wanner,Isabella Zwiener,Sabine Lauer,Jyothis T. George, Patrick Rossignol,Faı̈ez Zannad

Circulation（2019）

Cited0Views0Bibtex

Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes

Subodh Verma,Christoph Wanner,Isabella Zwiener,Anne Pernille Ofstad,Jyothis T. George,David Fitchett,Bernard Zinman

Journal of the American College of Cardiology（2019）

Cited32Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn

Associate Professor

Papers共 90 篇Author StatisticsCo-AuthorSimilar Experts